News | News By Subject | News by Disease News By Date | Search News

Cystic fibrosis News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Vertex (VRTX)’s Terminated Phase II CF Trial Was Planned     9/13/2017
Vertex (VRTX) Gains $8 Billion Overnight as Cystic Fibrosis Combo Drug Wows in Trials     7/21/2017
Tiny Massachusetts Phenom Corbus (CRBP) Plunges Despite Reporting Positive Phase II CF Data     3/30/2017
Vertex (VRTX) Inks Deal Worth $250 Million for Concert Pharma (CNCE)'s Cystic Fibrosis Drug     3/6/2017
Anthera Pharma (ANTH) Plunges After Cystic Fibrosis Drug Fails Late-Stage Trial     12/29/2016
A Crucial Need for Symptomatic Treatments Still Exists for Cystic Fibrosis Patients     12/5/2016
After Hep C Flop, Has Vertex (VRTX) Learned From Its Past Mistakes?     10/18/2016
Pharma Bro Warned You: Mast Therapeutics (MSTX) Craters After Drug Flunks Phase III Test, Job Cuts Expected     9/22/2016
Vertex (VRTX) Dumps Phase III Cystic Fibrosis Study     8/17/2016
Vertex (VRTX) and Moderna Hammer Out $315 Million+ Deal to Treat Cystic Fibrosis Using mRNA Technology     7/6/2016
FDA Spurns Vertex (VRTX) Application for Expanded Use of Kalydeco     2/5/2016
How Vertex (VRTX)'s Long-Term $500K Gamble Paid Off with a $30 Billion Return     11/18/2015
Vertex (VRTX)'s Success Spurs Startups Corbus and Pulmatrix to Enter Cystic Fibrosis Market     8/18/2015
Watch Out Gilead (GILD), Investors Feel Vertex (VRTX) May Be Biogen (BIIB)'s Good Fit     8/4/2015
Vertex (VRTX) Gets FDA Approval for $259K Per Year CF Drug     7/7/2015

News from Around the Web
For Vertex (VRTX), Can One Billion-Dollar Breakthrough Beget Another?     8/9/2017
Wearable Sweat Sensor Could Help Diagnose Diseases Like Diabetes, Cystic Fibrosis, Stanford University Study     4/18/2017
Is Vertex (VRTX)'s New CF Drug Unprecedented? Incremental? Expensive? Maybe All Three     3/30/2017
New Life Form Discovered In Saliva Is Linked To Human Disease, University of Washington Study     6/27/2016
VisiVest, A New Connected High-Frequency Chest-Wall Oscillation System, Hill-Rom Reveals     6/22/2016
The Importance Of Implementing CF Newborn Screening Reinforced, McGill University Study     5/5/2016
Researchers Build Promising CF Diagnostic System Using Microsoft's Xbox Kinect Sensors     3/30/2016
Fast, Accurate Cystic Fibrosis Test Developed At Stanford University     2/2/2016
Why Investors Shouldn't Freak Out Over Vertex (VRTX)'s Latest Trial Results     3/24/2015
Garlic Could Help Cure Lung Infection, University of Edinburgh Study     2/25/2015
University of Pittsburgh-Led Study Suggests Cystic Fibrosis Is Two Diseases, One Doesn’t Affect Lungs     7/23/2014
Cystic Fibrosis And Diabetes Link Explained, Lund University Study     6/3/2014
New Drug Target Found for Cystic Fibrosis Lung Disease, BC Children's Hospital Study     11/8/2012
Sea Sponge Chemical Fixes Cystic Fibrosis Defect, McGill University Study     10/29/2012
Differences Seen in Lung Microbes of Cystic Fibrosis Patients, Stanford University Study     10/1/2012

Press Releases
Motif BioSciences, Inc. Announces Iclaprim Granted Orphan Drug Designation By FDA For Treatment Of Staphylococcus Aureus Lung Infections In Patients With Cystic Fibrosis     9/15/2017
AIT Therapeutics’ Adjuvant Nitric Oxide Treatment Shown To Be Safe And Effective In The Compassionate Use Setting In Cystic Fibrosis Patients With Non-Tuberculous Mycobacteria (NTM) Infection     9/13/2017
Anthera Surpasses 50% Milestone For Screening Of Patients In RESULT Phase III Clinical Study Of Sollpura In Cystic Fibrosis     9/7/2017
ProQR Therapeutics (PRQR) Completes Dosing Of Cystic Fibrosis Patients In QR-010 Phase Ib Trial     8/29/2017
Vertex (VRTX) Announces Acceptance Of Its Applications For Review Of The Tezacaftor/Ivacaftor Combination Treatment In People With Cystic Fibrosis By The FDA And EMA     8/24/2017
Anthera Announces RESULT Phase III Clinical Study Of Sollpura Will Be Included In The European Cystic Fibrosis Clinical Trial Network     8/14/2017
Vertex (VRTX) Release: FDA Approves KALYDECO (Ivacaftor) For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations     8/1/2017
Proteostasis (PTI) Announces Progression Of PTI-428 And PTI-801 To Longer Duration Studies In CF Subjects     8/1/2017
Alcresta Announces Positive Results, Relizorb Increased Fat Absorption In Both Adult And Pediatric Patients With Cystic Fibrosis Receiving Enteral Nutrition     7/31/2017
Antabio Awarded Up To $8.9M From CARB-X To Accelerate The Development Of Its New Treatment For Chronic Infections In Cystic Fibrosis Patients     7/25/2017
Vertex (VRTX) Announces Reimbursement Agreement In Italy For ORKAMBI (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation     7/13/2017
Synspira’s Novel Glycopolymer Improves Effectiveness Of Antibiotics Against Drug-Resistant Bacteria Associated With Cystic Fibrosis     7/12/2017
Anthera Pharma (ANTH) Announces RESULT Phase III Clinical Study Of Sollpura Will Be Included In The Cystic Fibrosis Foundation Therapeutics Development Network     7/10/2017
Anthera Announces Expansion Of Screening In European Sites In Phase III RESULT Clinical Study Of Sollpura     7/6/2017
Proteostasis (PTI) Reports Preliminary Data From Phase I Study Of PTI-428 In Patients With Cystic Fibrosis     6/29/2017